InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007 and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI and New York, NY, USA. Source
No articles found.
Curis is a biotechnology company focused on the development and commercialization ...
Curis is a biotechnology company focused on the...
Castle Biosciences is a skin cancer diagnostics company focused on providing physi...
Castle Biosciences is a skin cancer diagnostics...
At MannKind Corporation (NASDAQ: MNKD), we focus on the discovery, development and...
At MannKind Corporation (NASDAQ: MNKD), we focu...
We are an innovative biopharmaceutical company developing therapies to treat the m...
We are an innovative biopharmaceutical company ...
Gemphire Therapeutics Inc. (NASDAQ:GEMP) is a clinicalâstage biopharmaceutical c...
Gemphire Therapeutics Inc. (NASDAQ:GEMP) is a c...
Cancer is one of the most difficult diseases to treat. It is constantly changing, ...
Cancer is one of the most difficult diseases to...
Dynavax Technologies Corporation (Nasdaq: DVAX) is a clinical-stage biopharmaceuti...
Dynavax Technologies Corporation (Nasdaq: DVAX)...
Hutchison China MediTech Limited, known as Chi-Med, is an innovative biopharmaceut...
Hutchison China MediTech Limited, known as Chi-...
We are a biotechnology company developing novel immunotherapy treatments for cance...
We are a biotechnology company developing novel...
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global ...
Celgene Corporation, headquartered in Summit, N...
Join the National Investor Network and get the latest information with your interests in mind.